Unlike gemtuzumab ozogamicin, which also targets normal cells, Brentuximab vedotin only targets CD30, which is an established marker for classic Hodgkin’s lymphoma, anaplastic large cell lymphoma and embryonal carcinomas [90–92]. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.